127 related articles for article (PubMed ID: 30697570)
1. Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort.
Chan A; Park L; Collins LF; Cooper C; Saag M; Dieterich D; Sulkowski M; Naggie S
Open Forum Infect Dis; 2019 Jan; 6(1):ofy273. PubMed ID: 30697570
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.
Brooks KM; Castillo-Mancilla JR; Morrow M; MaWhinney S; Blum J; Wyles DL; Rowan SE; Ibrahim ME; Zheng JH; Johnson B; Gomez J; Choi YJ; Cendali F; Haas H; Roon L; Bushman LR; Anderson PL; Kiser JJ
J Antimicrob Chemother; 2020 Nov; 75(11):3303-3310. PubMed ID: 32766700
[TBL] [Abstract][Full Text] [Related]
3. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.
Michal JL; Rab S; Patel M; Kyle AW; Miller LS; Easley KA; Kalapila AG
AIDS Res Hum Retroviruses; 2018 Aug; 34(8):690-698. PubMed ID: 29766745
[TBL] [Abstract][Full Text] [Related]
5. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
[TBL] [Abstract][Full Text] [Related]
6. Urine alpha1-microglobulin is a better marker for early tubular dysfunction than beta2-microglobulin among tenofovir-exposed human immunodeficiency virus-infected men who have sex with men.
Kang J; Liu J; Ding H; Li X; Wang Q; Guo X; Geng W; Shang H
Braz J Infect Dis; 2015; 19(4):410-6. PubMed ID: 26119851
[TBL] [Abstract][Full Text] [Related]
7. Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy.
Nishijima T; Kurosawa T; Tanaka N; Kawasaki Y; Kikuchi Y; Oka S; Gatanaga H
AIDS; 2016 Jun; 30(10):1563-71. PubMed ID: 26919734
[TBL] [Abstract][Full Text] [Related]
8. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Gupta SK; Post FA; Arribas JR; Eron JJ; Wohl DA; Clarke AE; Sax PE; Stellbrink HJ; Esser S; Pozniak AL; Podzamczer D; Waters L; Orkin C; Rockstroh JK; Mudrikova T; Negredo E; Elion RA; Guo S; Zhong L; Carter C; Martin H; Brainard D; SenGupta D; Das M
AIDS; 2019 Jul; 33(9):1455-1465. PubMed ID: 30932951
[TBL] [Abstract][Full Text] [Related]
9. Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study.
Rodríguez-Nóvoa S; García-Samaniego J; Prieto M; Calleja JL; Pascasio JM; Delgado Blanco M; Crespo J; Buti M; Bonet Vidal ML; Arenas Ruiz Tapiador J; Fernández-Rodríguez C; Solá R; Fraga E; González Diéguez L; Núñez O; Praga M; Del Pino-Montes J; Romero-Gómez M; Morillas R; Diago M; Castro Á;
J Clin Gastroenterol; 2016 Oct; 50(9):779-89. PubMed ID: 27332746
[TBL] [Abstract][Full Text] [Related]
10. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.
Hall AM; Edwards SG; Lapsley M; Connolly JO; Chetty K; O'Farrell S; Unwin RJ; Williams IG
Am J Kidney Dis; 2009 Dec; 54(6):1034-42. PubMed ID: 19783343
[TBL] [Abstract][Full Text] [Related]
11. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.
Gatanaga H; Tachikawa N; Kikuchi Y; Teruya K; Genka I; Honda M; Tanuma J; Yazaki H; Ueda A; Kimura S; Oka S
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):744-8. PubMed ID: 16910829
[TBL] [Abstract][Full Text] [Related]
12. Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients.
Seo JW; Kim K; Jun KI; Kang CK; Moon SM; Song KH; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Choe PG; Park WB; Oh MD
Infect Chemother; 2020 Sep; 52(3):381-388. PubMed ID: 32757496
[TBL] [Abstract][Full Text] [Related]
13. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
Gallant JE; Winston JA; DeJesus E; Pozniak AL; Chen SS; Cheng AK; Enejosa JV
AIDS; 2008 Oct; 22(16):2155-63. PubMed ID: 18832879
[TBL] [Abstract][Full Text] [Related]
14. Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.
Brooks KM; Castillo-Mancilla JR; Blum J; Huntley R; MaWhinney S; Alexander K; Kerr BJ; Ellison L; Bushman LR; MacBrayne CE; Anderson PL; Kiser JJ
J Antimicrob Chemother; 2019 Aug; 74(8):2360-2364. PubMed ID: 31081036
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment.
Calcagno A; Cusato J; Marinaro L; Simiele M; Lucchiari M; Alcantarini C; Tettoni MC; Trentini L; Mengozzi G; D'Avolio A; Di Perri G; Bonora S
AIDS; 2016 Mar; 30(6):915-20. PubMed ID: 26636928
[TBL] [Abstract][Full Text] [Related]
16. Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide.
Custodio JM; Chuck SK; Chu H; Cao H; Ma G; Flaherty J; Ling J; Kearney BP
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971607
[TBL] [Abstract][Full Text] [Related]
17. Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.
Ikeda M; Wakabayashi Y; Okamoto K; Yanagimoto S; Okugawa S; Moriya K
AIDS Res Ther; 2021 May; 18(1):30. PubMed ID: 34044856
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
[TBL] [Abstract][Full Text] [Related]
19. Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
Hamzah L; Williams D; Bailey AC; Jones R; Ibrahim F; Musso CG; Burling K; Barbini B; Campbell L; Post FA;
HIV Med; 2020 Mar; 21(3):198-203. PubMed ID: 31679186
[TBL] [Abstract][Full Text] [Related]
20. Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity.
Sise ME; Hirsch JS; Canetta PA; Herlitz L; Mohan S
AIDS; 2015 May; 29(8):941-6. PubMed ID: 25784440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
